MedTrace Logo

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01678924 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2020-01-07

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

AGN-214868

AGN-214868 given as injections into the area of pain on Day 1.

DRUG

AGN-214868 Placebo (Vehicle)

AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-05-31
Completion
2015-09-30

Countries

  • United States
  • Austria
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678924 on ClinicalTrials.gov